Is Ironwood Pharmaceuticals Stock a Good Investment?
Ironwood Pharmaceuticals Investment Advice | IRWD |
- Examine Ironwood Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Ironwood Pharmaceuticals' leadership team and their track record. Good management can help Ironwood Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Ironwood Pharmaceuticals' business and its evolving consumer preferences.
- Compare Ironwood Pharmaceuticals' performance and market position to its competitors. Analyze how Ironwood Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Ironwood Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Ironwood Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Ironwood Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Ironwood Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Ironwood Pharmaceuticals Stock
Researching Ironwood Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 6.78. Ironwood Pharmaceuticals last dividend was issued on the 2nd of April 1970. The entity had 1194:1000 split on the 2nd of April 2019.
To determine if Ironwood Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ironwood Pharmaceuticals' research are outlined below:
| Ironwood Pharmaceuticals generated a negative expected return over the last 90 days | |
| Ironwood Pharmaceuticals has high historical volatility and very poor performance | |
| Ironwood Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 442.74 M. Net Loss for the year was (1 B) with profit before overhead, payroll, taxes, and interest of 366.33 M. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Ironwood Pharmaceuticals Stock Price Down 2.4 percent - MarketBeat |
Ironwood Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ironwood Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ironwood Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Ironwood Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Ironwood Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-05-06 | 2020-03-31 | 0.05 | 0.04 | -0.01 | 20 | ||
2011-05-12 | 2011-03-31 | -0.17 | -0.19 | -0.02 | 11 | ||
2011-03-03 | 2010-12-31 | -0.14 | -0.12 | 0.02 | 14 | ||
2021-05-06 | 2021-03-31 | 0.21 | 0.24 | 0.03 | 14 | ||
2018-05-01 | 2018-03-31 | -0.23 | -0.27 | -0.04 | 17 | ||
2018-02-15 | 2017-12-31 | -0.18 | -0.14 | 0.04 | 22 | ||
2017-11-02 | 2017-09-30 | -0.22 | -0.18 | 0.04 | 18 | ||
2016-05-09 | 2016-03-31 | -0.13 | -0.09 | 0.04 | 30 |
Ironwood Pharmaceuticals Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ironwood target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Ironwood Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Strong Buy |
Most Ironwood analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Ironwood stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Ironwood Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationIronwood Pharmaceuticals Target Price Projection
Ironwood Pharmaceuticals' current and average target prices are 6.62 and 16.50, respectively. The current price of Ironwood Pharmaceuticals is the price at which Ironwood Pharmaceuticals is currently trading. On the other hand, Ironwood Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Ironwood Pharmaceuticals Market Quote on 17th of May 2024
Target Price
Analyst Consensus On Ironwood Pharmaceuticals Target Price
Ironwood Pharmaceuticals Analyst Ratings
Ironwood Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Ironwood Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Ironwood Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Ironwood Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.Know Ironwood Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ironwood Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ironwood Pharmaceuticals backward and forwards among themselves. Ironwood Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Ironwood Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jupiter Asset Management Limited | 2023-12-31 | 2.3 M | Goldman Sachs Group Inc | 2023-12-31 | 2.2 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 2.1 M | Nuveen Asset Management, Llc | 2023-12-31 | 1.8 M | Northern Trust Corp | 2023-12-31 | 1.6 M | Driehaus Capital Management Llc | 2023-12-31 | 1.6 M | Adage Capital Partners Gp Llc | 2023-12-31 | 1.5 M | Jpmorgan Chase & Co | 2023-12-31 | 1.5 M | Man Group Plc | 2023-12-31 | 1.4 M | Blackrock Inc | 2023-12-31 | 26 M | Vanguard Group Inc | 2023-12-31 | 16 M |
Ironwood Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.04 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ironwood Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Ironwood Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Ironwood Pharmaceuticals' profitablity analysis
Ironwood Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Ironwood Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Ironwood Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Ironwood Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Ironwood Pharmaceuticals' profitability requires more research than a typical breakdown of Ironwood Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.14) | (2.04) | |
| Return On Capital Employed | 1.07 | 1.13 | |
| Return On Assets | (2.13) | (2.02) | |
| Return On Equity | 2.89 | 3.04 |
Determining Ironwood Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Ironwood Pharmaceuticals is a good buy. For example, gross profit margin measures Ironwood Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ironwood Pharmaceuticals' profitability and make more informed investment decisions.
Ironwood Pharmaceuticals' Earnings Breakdown by Geography
The data published in Ironwood Pharmaceuticals' official financial statements usually reflect Ironwood Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Ironwood Pharmaceuticals. For example, before you start analyzing numbers published by Ironwood accountants, it's critical to develop an understanding of what Ironwood Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Ironwood Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ironwood Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Ironwood Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Ironwood Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Ironwood Pharmaceuticals' management manipulating its earnings.
Evaluate Ironwood Pharmaceuticals' management efficiency
Ironwood Pharmaceuticals has return on total asset (ROA) of 0.0939 % which means that it generated a profit of $0.0939 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7472) %, meaning that it created substantial loss on money invested by shareholders. Ironwood Pharmaceuticals' management efficiency ratios could be used to measure how well Ironwood Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Ironwood Pharmaceuticals' Return On Equity is projected to slightly grow based on the last few years of reporting. At present, Ironwood Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 356.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 3.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.23) | (2.34) | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | (2.25) | (2.36) | |
| Enterprise Value Over EBITDA | 11.40 | 11.97 | |
| Price Book Value Ratio | (5.13) | (4.88) | |
| Enterprise Value Multiple | 11.40 | 11.97 | |
| Price Fair Value | (5.13) | (4.88) | |
| Enterprise Value | 2.2 B | 2.4 B |
The analysis of Ironwood Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Ironwood Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Ironwood Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.575 |
Basic technical analysis of Ironwood Stock
As of the 17th of May 2024, Ironwood Pharmaceuticals retains the Standard Deviation of 5.62, market risk adjusted performance of 12.47, and Risk Adjusted Performance of (0.10). Ironwood Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We are able to interpolate and break down thirteen technical drivers for Ironwood Pharmaceuticals, which can be compared to its competitors. Please check out Ironwood Pharmaceuticals information ratio and skewness to decide if Ironwood Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 6.62 per share. Given that Ironwood Pharmaceuticals has information ratio of (0.21), we strongly advise you to confirm Ironwood Pharmaceuticals's regular market performance to make sure the company can sustain itself at a future point.Ironwood Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ironwood Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ironwood Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ironwood Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sravan Emany over three weeks ago Disposition of 41332 shares by Sravan Emany of Ironwood Pharmaceuticals at 14.9 subject to Rule 16b-3 | ||
Denner Alexander J over two months ago Acquisition by Denner Alexander J of 1662 shares of Ironwood Pharmaceuticals subject to Rule 16b-3 | ||
Vr Management Llc over six months ago Acquisition by Vr Management Llc of 181 shares of Ironwood Pharmaceuticals subject to Rule 16b-3 |
Ironwood Pharmaceuticals' Outstanding Corporate Bonds
Ironwood Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ironwood Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ironwood bonds can be classified according to their maturity, which is the date when Ironwood Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US46333XAF50 Corp BondUS46333XAF50 | View | |
| US46333XAH17 Corp BondUS46333XAH17 | View |
Understand Ironwood Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Ironwood Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | 12.47 | |||
| Mean Deviation | 2.81 | |||
| Coefficient Of Variation | (533.68) | |||
| Standard Deviation | 5.62 | |||
| Variance | 31.57 | |||
| Information Ratio | (0.21) | |||
| Jensen Alpha | (1.05) | |||
| Total Risk Alpha | (2.00) | |||
| Treynor Ratio | 12.46 | |||
| Maximum Drawdown | 39.72 | |||
| Value At Risk | (5.65) | |||
| Potential Upside | 3.86 | |||
| Skewness | (4.66) | |||
| Kurtosis | 28.43 |
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | 12.47 | |||
| Mean Deviation | 2.81 | |||
| Coefficient Of Variation | (533.68) | |||
| Standard Deviation | 5.62 | |||
| Variance | 31.57 | |||
| Information Ratio | (0.21) | |||
| Jensen Alpha | (1.05) | |||
| Total Risk Alpha | (2.00) | |||
| Treynor Ratio | 12.46 | |||
| Maximum Drawdown | 39.72 | |||
| Value At Risk | (5.65) | |||
| Potential Upside | 3.86 | |||
| Skewness | (4.66) | |||
| Kurtosis | 28.43 |
Consider Ironwood Pharmaceuticals' intraday indicators
Ironwood Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ironwood Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 6.62 | |||
| Day Typical Price | 6.62 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.02) |
Ironwood Pharmaceuticals Corporate Filings
8K | 9th of May 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 25th of April 2024 Other Reports | ViewVerify | |
F4 | 19th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 16th of February 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Ironwood Stock media impact
Far too much social signal, news, headlines, and media speculation about Ironwood Pharmaceuticals that are available to investors today. That information is available publicly through Ironwood media outlets and privately through word of mouth or via Ironwood internal channels. However, regardless of the origin, that massive amount of Ironwood data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ironwood Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ironwood Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ironwood Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ironwood Pharmaceuticals alpha.
Ironwood Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Ironwood Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ironwood Pharmaceuticals Historical Investor Sentiment
Investor biases related to Ironwood Pharmaceuticals' public news can be used to forecast risks associated with an investment in Ironwood. The trend in average sentiment can be used to explain how an investor holding Ironwood can time the market purely based on public headlines and social activities around Ironwood Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ironwood Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ironwood Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Ironwood Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Ironwood Pharmaceuticals.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Ironwood Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Crypto Correlations Now
Crypto CorrelationsUse cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
| All Next | Launch Module |
Ironwood Pharmaceuticals Corporate Management
Elected by the shareholders, the Ironwood Pharmaceuticals' board of directors comprises two types of representatives: Ironwood Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ironwood. The board's role is to monitor Ironwood Pharmaceuticals' management team and ensure that shareholders' interests are well served. Ironwood Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ironwood Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas McCourt | Chief Commercial Officer and Sr. VP of Marketing and Sales | Profile | |
| Jana Noeldeke | Basel Leader | Profile | |
| Ronald Silver | Corporate Officer | Profile | |
| Marcel Moulaison | Vice Operations | Profile | |
| Beth Calitri | Head Relations | Profile | |
| Sravan Emany | Principal VP | Profile |
How to buy Ironwood Stock?
To provide specific investment advice or recommendations on Ironwood Pharmaceuticals stock, we recommend investors consider the following general factors when evaluating Ironwood Pharmaceuticals. This will help you to make an informed decision on whether to include Ironwood Pharmaceuticals in one of your diversified portfolios:- Examine Ironwood Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Ironwood Pharmaceuticals' leadership team and their track record. Good management can help Ironwood Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Ironwood Pharmaceuticals' business and its evolving consumer preferences.
- Compare Ironwood Pharmaceuticals' performance and market position to its competitors. Analyze how Ironwood Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Ironwood Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Ironwood Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Ironwood Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Ironwood Pharmaceuticals is a good investment.
Already Invested in Ironwood Pharmaceuticals?
The danger of trading Ironwood Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Ironwood Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Ironwood Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Ironwood Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Stocks Directory Find actively traded stocks across global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Ironwood Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.69) | Earnings Share (6.78) | Revenue Per Share 2.647 | Quarterly Revenue Growth (0.28) | Return On Assets 0.0939 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Ironwood Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.